Brief: Immunicum AB - Receives Orphan Drug Designation From EMA

Mendus AB (publ)

19/02/2021 07:14

Feb 19 (Reuters) - Immunicum AB  IMMUN.ST :
    * REG-IMMUNICUM AB (PUBL) RECEIVES ORPHAN DRUG DESIGNATION FROM EMA FOR ILIXADENCEL AS
TREATMENT
FOR GASTROINTESTINAL STROMAL TUMORS (GIST)
    * IMMUNICUM AB - COMP OPINION WAS BASED ON RESULTS FROM PHASE I/II CLINICAL TRIAL IN GIST, A
RARE
AND DIFFICULT-TO TREAT CANCER INDICATION BELONGING TO GROUP OF CANCERS REFERRED TO AS SOFT
TISSUE SARCOMAS (STS).

Source text for Eikon:  ID:nGNEN94Qt 
Further company coverage:  IMMUN.ST 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))